Accelerate global market access while ensuring the highest standards of patient safety with Masuu Global Solutions’ Biocompatibility Compliance Services. From ISO 10993 risk assessments to complete biological evaluations, we provide end‑to‑end support that helps manufacturers meet worldwide regulatory requirements with precision and confidence.
Our experts combine scientific rigor, regulatory insight, and efficient methodologies to help you demonstrate biological safety, reduce unnecessary testing, and achieve faster regulatory approvals.
OverviewAt Masuu Global Solutions, we recognize that patient safety is the foundation of every medical device. Biocompatibility evaluation is a critical component of global regulatory submissions—ensuring that device materials interact safely with the human body under intended use conditions.
With increasingly stringent standards across ISO 10993, EU MDR, and other international frameworks, manufacturers need a trusted partner who can navigate biological evaluation requirements with accuracy, clarity, and efficiency.
- Reduce the need for animal testing through risk‑based approaches
- Optimize biological evaluations with the latest scientific methodologies
- Support quicker and smoother approvals across global markets
- Strengthen patient safety and long‑term device performance
Partnering with Masuu gives you access to scientific toxicologists, risk assessors, and regulatory experts dedicated to guiding your device from concept to commercialization.
Our Comprehensive Biocompatibility Services Masuu Global Solutions offers a full suite of services to help manufacturers meet biological safety requirements across different device categories and market regions. ✔ Biological Evaluation (ISO 10993 & EU MDR) Complete biological evaluations that incorporate device materials, design, intended patient exposure, and real‑world use. We ensure all evaluations align with:- ISO 10993‑1: Biological Evaluation Framework
- EU MDR Annex I (GSPRs)
- FDA and international biological safety expectations
- Addresses testing gaps
- Minimizes redundant studies
- Ensures full alignment with ISO 10993 & MDR requirements
- Reduces delays during Notified Body or FDA review
- Identification of extractable/leachable chemicals
- Quantification of substance concentrations
- Toxicological hazard characterization
- Exposure and margin of safety calculations
- ISO 10993‑17‑aligned safety justifications
- Reduce testing burden
- Decrease time‑to‑market
- Support comparative safety justification
- Strengthen regulatory submissions
- Severity
- Probability
- Extent of patient exposure
- Material‑related hazards
- Chemical exposures
- Use‑related biological risks
- Long‑term safety concerns
- Device materials
- Physical and chemical characterization
- Intended use & duration of contact
- ISO 10993 test selection
- Explain testing decisions
- Support alternative methods in place of animal tests
- Provide transparent, data‑driven conclusions
- Strengthen your submission’s biological safety narrative
- Biological endpoints applicable to your device
- Material characterization strategy
- Rationale for test selection and exclusions
- All regulatory, scientific, and toxicological inputs
- Comprehensive review of all test results
- Toxicological assessment of extractables & leachables
- Integration of chemical, biological, and clinical evidence
- Final conclusions supporting biological safety and compliance
